$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000090670921000005 Filed on February 26, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$23.46M	$33.86M	$29.22M
YoY Change	-30.71%	-14.98%	5.24%
Cost Of Revenue	$4.323M	$5.989M	$4.927M
YoY Change	-27.82%	-19.73%	3.01%
Gross Profit	$19.14M	$27.87M	$24.29M
YoY Change	-31.33%	-13.88%	5.71%
Gross Profit Margin	81.57%	82.31%	83.14%
Selling, General & Admin	$27.10M	$27.10M	$24.00M
YoY Change	0.0%	13.87%	28.34%
% of Gross Profit	141.6%	97.23%	98.8%
Research & Development	$102.7M	$110.4M	$99.05M
YoY Change	-6.93%	1.36%	-3.74%
% of Gross Profit	536.73%	395.97%	407.76%
Depreciation & Amortization	$3.300M	$3.600M	$3.500M
YoY Change	-8.33%	16.13%	29.63%
% of Gross Profit	17.24%	12.92%	14.41%
Operating Expenses	$102.7M	$110.4M	$99.05M
YoY Change	-6.93%	1.36%	-3.74%
Operating Profit	-$110.7M	-$109.6M	-$98.74M
YoY Change	0.99%	9.32%	0.11%
Interest Expense	-$6.400M	-$2.200M	$5.425M
YoY Change	190.91%	-1200.0%	-0.31%
% of Operating Profit
Other Income/Expense, Net			$254.0K
YoY Change			-84.04%
Pretax Income	-$117.1M	-$111.9M	-$98.49M
YoY Change	4.65%	11.79%	1.49%
Income Tax	$100.0K	$1.500M	$99.00K
% Of Pretax Income
Net Earnings	-$117.2M	-$112.2M	-$98.59M
YoY Change	4.49%	14.21%	2.54%
Net Earnings / Revenue	-499.54%	-331.24%	-337.41%
Basic Earnings Per Share	-$0.65	-$0.64	-$0.56
Diluted Earnings Per Share	-$0.65	-$0.64	-$0.56
COMMON SHARES
Basic Shares Outstanding	179.4M shares	175.9M shares	175.4M shares
Diluted Shares Outstanding			175.4M shares

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.062B	$1.325B	$1.496B
YoY Change	-19.85%	-0.79%	5.3%
Cash & Equivalents	$199.0M	$96.36M	$81.22M
Short-Term Investments	$862.9M	$1.228B	$1.414B
Other Short-Term Assets	$21.93M	$15.39M	$15.21M
YoY Change	42.51%	-27.74%	21.31%
Inventory	$15.29M	$12.67M	$13.72M
Prepaid Expenses
Receivables	$38.89M	$36.80M	$41.21M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.138B	$1.422B	$1.579B
YoY Change	-19.95%	-1.12%	4.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.66M	$65.67M	$64.61M
YoY Change	-9.14%	34.42%	43.91%
Goodwill	$76.50M	$76.50M	$76.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$136.7M	$279.1M	$231.1M
YoY Change	-51.02%	-52.12%	-62.67%
Other Assets	$1.461M	$344.0K	$2.385M
YoY Change	324.71%	-91.89%	-29.85%
Total Long-Term Assets	$400.8M	$555.8M	$509.5M
YoY Change	-27.9%	-21.99%	-31.52%
TOTAL ASSETS
Total Short-Term Assets	$1.138B	$1.422B	$1.579B
Total Long-Term Assets	$400.8M	$555.8M	$509.5M
Total Assets	$1.539B	$1.977B	$2.088B
YoY Change	-22.18%	-8.04%	-7.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.14M	$19.23M	$21.96M
YoY Change	15.1%	228.56%	192.84%
Accrued Expenses	$93.50M	$79.50M	$95.00M
YoY Change	17.61%	28.64%	21.33%
Deferred Revenue	$91.00K	$5.517M	$8.400M
YoY Change	-98.35%	-60.29%	-46.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$248.7M
YoY Change	-100.0%
Total Short-Term Liabilities	$115.8M	$353.9M	$125.4M
YoY Change	-67.28%	331.57%	15.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$248.3M
YoY Change		-100.0%	0.73%
Other Long-Term Liabilities	$8.980M	$768.0K	$643.0K
YoY Change	1069.27%	-92.31%	-99.38%
Total Long-Term Liabilities	$8.980M	$768.0K	$643.0K
YoY Change	1069.27%	-92.31%	-99.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.8M	$353.9M	$125.4M
Total Long-Term Liabilities	$8.980M	$768.0K	$643.0K
Total Liabilities	$461.5M	$572.0M	$599.6M
YoY Change	-19.32%	32.22%	30.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.309B	-$1.865B	-$1.751B
YoY Change	23.83%	30.94%
Common Stock	$3.389B	$3.271B	$3.241B
YoY Change	3.6%	3.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.077B	$1.405B	$1.489B
YoY Change
Total Liabilities & Shareholders Equity	$1.539B	$1.977B	$2.088B
YoY Change	-22.18%	-8.04%	-7.15%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$117.2M	-$112.2M	-$98.59M
YoY Change	4.49%	14.21%	2.54%
Depreciation, Depletion And Amortization	$3.300M	$3.600M	$3.500M
YoY Change	-8.33%	16.13%	29.63%
Cash From Operating Activities	-$98.60M	-$125.2M	-$68.70M
YoY Change	-21.25%	6.46%	-3.78%
INVESTING ACTIVITIES
Capital Expenditures	-$1.800M	-$3.700M	-$5.300M
YoY Change	-51.35%	-56.98%	178.95%
Acquisitions
YoY Change
Other Investing Activities	$94.50M	$139.2M	$63.60M
YoY Change	-32.11%	44.7%	-110.27%
Cash From Investing Activities	$92.70M	$135.5M	$58.20M
YoY Change	-31.59%	54.68%	-109.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	148.9M	5.000M	6.200M
YoY Change	2878.0%	85.19%	58.97%
NET CHANGE
Cash From Operating Activities	-98.60M	-125.2M	-68.70M
Cash From Investing Activities	92.70M	135.5M	58.20M
Cash From Financing Activities	148.9M	5.000M	6.200M
Net Change In Cash	143.0M	15.30M	-4.300M
YoY Change	834.64%	-156.04%	-99.38%
FREE CASH FLOW
Cash From Operating Activities	-$98.60M	-$125.2M	-$68.70M
Capital Expenditures	-$1.800M	-$3.700M	-$5.300M
Free Cash Flow	-$96.80M	-$121.5M	-$63.40M
YoY Change	-20.33%	11.47%	-8.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2020	nktr	Royalty Agreement Contingent Payment Description RoyaltyAgreementContingentPaymentDescription	As a result of worldwide net sales of MIRCERA® for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.
CY2020	nktr	Percentage Of Net Sales To Fund External Costs Incurred Due To Reduction Of2 Percentage Points PercentageOfNetSalesToFundExternalCostsIncurredDueToReductionOf2PercentagePoints	0.02
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	0-24006
CY2020	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2020	dei	City Area Code CityAreaCode	415
CY2020	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2020	dei	Trading Symbol TradingSymbol	NKTR
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	4100000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	182182063	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38889000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36802000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
CY2020Q4	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	3908000	USD
CY2019Q4	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	31834000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18020000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15387000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1138005000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1421550000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65665000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126476000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	134177000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1461000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	344000	USD
CY2020Q4	us-gaap	Assets Assets	1538767000	USD
CY2019Q4	us-gaap	Assets Assets	1977356000	USD
CY2020Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	0	USD
CY2019Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	252891000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22139000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19234000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14532000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11467000	USD
CY2020Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	44207000	USD
CY2019Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	32626000	USD
CY2020Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	11310000	USD
CY2019Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	7304000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9585000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12338000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13915000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12516000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	91000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5517000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115779000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	353893000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136373000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	142730000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2019Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	72020000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2464000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2554000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6516000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	768000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	461472000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	571965000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	180091000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180091000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	176505000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176505000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3388730000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3271097000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2295000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1005000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2309158000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1864718000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1538767000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1977356000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114617000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1193323000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19477000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21374000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24412000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408678000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	434566000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399536000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104682000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	98712000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81443000	USD
CY2020	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	45189000	USD
CY2019	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	0	USD
CY2018	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	578026000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	554652000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	505391000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-425111000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-440035000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	687932000	USD
CY2020	us-gaap	Interest Expense InterestExpense	6851000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Interest Expense InterestExpense	21310000	USD
CY2018	us-gaap	Interest Expense InterestExpense	21582000	USD
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	USD
CY2019	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25044000	USD
CY2018	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	21196000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18282000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46335000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37571000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18836000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5207000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-440054000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	682725000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1412000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-440667000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	681313000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.49
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.52
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.49
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.52
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.78
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	178581000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174993000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	169600000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	178581000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174993000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	180119000	shares
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-440667000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	681313000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-927000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5693000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2975000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-363000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-382000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1230000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1290000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5311000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4205000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435356000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	677108000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	87828000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2100000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	61729000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	88101000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	790232000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	677108000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23377000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	99795000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435356000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23373000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94261000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-444440000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-440667000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	681313000	USD
CY2020	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	48563000	USD
CY2019	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	36303000	USD
CY2018	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	33308000	USD
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	USD
CY2019	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25044000	USD
CY2018	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	21196000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99795000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88101000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14182000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13156000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10870000	USD
CY2020	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
CY2019	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2018	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2020	nktr	Accretion Of Discount Net And Other Non Cash Transactions AccretionOfDiscountNetAndOtherNonCashTransactions	-3943000	USD
CY2019	nktr	Accretion Of Discount Net And Other Non Cash Transactions AccretionOfDiscountNetAndOtherNonCashTransactions	11394000	USD
CY2018	nktr	Accretion Of Discount Net And Other Non Cash Transactions AccretionOfDiscountNetAndOtherNonCashTransactions	10952000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1913000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6411000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25505000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2627000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1284000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	655000	USD
CY2020	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2743000	USD
CY2019	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-13090000	USD
CY2018	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4476000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1190000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	31652000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2382000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12967000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	971000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4697000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1530000	USD
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1674000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	8644000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4349000	USD
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	31492000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5516000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16565000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15331000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-313287000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-328681000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	718214000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	987533000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1380865000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2271250000	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	8100000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1449304000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1614036000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	890957000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11963000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7258000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26285000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14239000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2633000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	496213000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	206886000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1379936000	USD
CY2020	nktr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	USD
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6800000	USD
CY2019	nktr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	USD
CY2018	nktr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	790231000	USD
CY2020	nktr	Sale Of Future Royalties Transaction Costs SaleOfFutureRoyaltiesTransactionCosts	3800000	USD
CY2020	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	146250000	USD
CY2019	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2018	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	250000000	USD
CY2019	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2018	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23396000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23355000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	61735000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-80354000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23355000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	851966000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-102000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-101000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102592000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-98542000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	190143000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4762000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9742000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	19199000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	19471000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	539000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	555000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	618000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	57691000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1200000000	USD
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
CY2020	nktr	Net Expense Reimbursements From Collaboration Partner NetExpenseReimbursementsFromCollaborationPartner	38700000	USD
CY2020	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	200000	USD
CY2019	nktr	Net Expense Reimbursements From Collaboration Partner NetExpenseReimbursementsFromCollaborationPartner	24000000.0	USD
CY2019	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	12800000	USD
CY2019	nktr	Contract With Customer Estimate For Royalties Resulting From Net Sales ContractWithCustomerEstimateForRoyaltiesResultingFromNetSales	11600000	USD
CY2020	nktr	Number Of Reporting Units To Evaluate Goodwill For Impairment NumberOfReportingUnitsToEvaluateGoodwillForImpairment	1	reporting_unit
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10500000	shares
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	12000000.0	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	5100000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6500000	USD
CY2020Q4	us-gaap	Cash Cash	6285000	USD
CY2019Q4	us-gaap	Cash Cash	5829000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2422000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1673000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10703000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8267000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2167000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2725000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
CY2018	us-gaap	Lease Cost LeaseCost	12469000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	19000000.0	USD
CY2020Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	193450000	USD
CY2019Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	188322000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	138488000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	127875000	USD
CY2020Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	54962000	USD
CY2019Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	60447000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	4700000	USD
CY2019Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	5218000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65665000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12500000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000000.0	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8800000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	18985000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	14697000	USD
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	7972000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	8179000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	6408000	USD
CY2018	us-gaap	Variable Lease Cost VariableLeaseCost	4497000	USD
CY2020	us-gaap	Lease Cost LeaseCost	27164000	USD
CY2019	us-gaap	Lease Cost LeaseCost	21105000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	14700000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	16200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8400000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17938000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	20141000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20780000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	21439000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	22117000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	97764000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	200179000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	46380000	USD
CY2020Q4	nktr	Lessee Operating Lease Liability Tenant Improvement Reimbursements LesseeOperatingLeaseLiabilityTenantImprovementReimbursements	3511000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	150288000	USD
CY2020	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13915000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136373000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
CY2019Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	73551000	USD
CY2012Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	0	USD
CY2020	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	150000000	USD
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000	USD
CY2020	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	48563000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	255705000	USD
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	196960000	USD
CY2020	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	0	USD
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	205255000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	205255000	USD
CY2020Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	4915000	USD
CY2020Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	4915000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2020Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	8000000.0	USD
CY2018Q2	nktr	Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod	P5Y
CY2020Q4	nktr	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding	20894000	shares
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2800000	USD
CY2020	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2020	nktr	Change In Control Severance Payment Period For Chief Executive Officer ChangeInControlSeverancePaymentPeriodForChiefExecutiveOfficer	P24M
CY2020	nktr	Change In Control Severance Payment Period For Senior Vice Presidents And Vice Presidents ChangeInControlSeverancePaymentPeriodForSeniorVicePresidentsAndVicePresidents	P12M
CY2020	nktr	Change In Control Severance Payment Period For Employees ChangeInControlSeverancePaymentPeriodForEmployees	P6M
CY2020	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	55849000	USD
CY2019	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	16975000	USD
CY2018	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	1097265000	USD
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	129600000	USD
CY2019	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	77500000	USD
CY2018	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	95300000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8071000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5516000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2555000	USD
CY2020Q4	nktr	Potential Development Milestones PotentialDevelopmentMilestones	1700000000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99795000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88101000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	193700000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M14D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.641
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.622
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.610
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.70
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.25
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	29.86
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14885000	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	303400000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.23
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1654000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.15
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1669000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.69
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1233000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	45.70
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13637000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.30
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23478000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9523000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.99
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M15D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23468000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15900000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	30600000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-445370000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-441494000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	680423000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1423000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1440000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2302000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-440054000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	682725000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	165000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	139000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	699000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	364000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	495000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	620000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	529000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	634000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1319000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-36000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-21000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	93000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-36000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-21000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	93000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1412000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-93229000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-92411000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	143372000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3081000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10511000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	17295000	USD
CY2020	nktr	Income Tax Reconciliation Premium On Equity Issuance IncomeTaxReconciliationPremiumOnEquityIssuance	0	USD
CY2019	nktr	Income Tax Reconciliation Premium On Equity Issuance IncomeTaxReconciliationPremiumOnEquityIssuance	0	USD
CY2018	nktr	Income Tax Reconciliation Premium On Equity Issuance IncomeTaxReconciliationPremiumOnEquityIssuance	12551000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	87060000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	104440000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-46885000	USD
CY2020	nktr	Income Tax Reconciliation Expense Share Based Compensation Cost IncomeTaxReconciliationExpenseShareBasedCompensationCost	7929000	USD
CY2019	nktr	Income Tax Reconciliation Expense Share Based Compensation Cost IncomeTaxReconciliationExpenseShareBasedCompensationCost	-672000	USD
CY2018	nktr	Income Tax Reconciliation Expense Share Based Compensation Cost IncomeTaxReconciliationExpenseShareBasedCompensationCost	-66716000	USD
CY2020	nktr	Incometax Reconciliation Income Tax Sale Of Future Royalties IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties	-7967000	USD
CY2019	nktr	Incometax Reconciliation Income Tax Sale Of Future Royalties IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties	-7624000	USD
CY2018	nktr	Incometax Reconciliation Income Tax Sale Of Future Royalties IncometaxReconciliationIncomeTaxSaleOfFutureRoyalties	-6995000	USD
CY2020	nktr	Income Tax Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties	6356000	USD
CY2019	nktr	Income Tax Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties	5259000	USD
CY2018	nktr	Income Tax Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties IncomeTaxReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyalties	4451000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3425000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2132000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4031000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1412000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	456284000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	399361000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	132994000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	128015000	USD
CY2020Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	35672000	USD
CY2019Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	36907000	USD
CY2020Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	32737000	USD
CY2019Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	32517000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30875000	USD
CY2020Q4	nktr	Deferred Tax Assets Depreciation Property And Equipment DeferredTaxAssetsDepreciationPropertyAndEquipment	11688000	USD
CY2019Q4	nktr	Deferred Tax Assets Depreciation Property And Equipment DeferredTaxAssetsDepreciationPropertyAndEquipment	13568000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	701892000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	608726000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	670103000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	575087000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	31789000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33639000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	29707000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	31718000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1856000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1725000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	31563000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	33443000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	226000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	196000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-95000000.0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-114600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	77410000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27419000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20483000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2512000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	49858000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5664000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	193000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	277000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1272000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1450000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	144000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	77410000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27419000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2020	nktr	Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange	P12M
CY2020	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2020	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114617000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1193323000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50573000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48847000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30033000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23462000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28222000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23315000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29218000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33862000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3811000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5773000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5570000	USD
CY2020Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4323000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5440000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5018000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4927000	USD
CY2019Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5989000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108987000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96436000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100531000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102724000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118463000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	106686000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99048000	USD
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110369000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133631000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-77709000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-103050000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-110721000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-120687000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-110970000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-98740000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-109638000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-80000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-117203000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-119632000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-110286000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-98585000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-112164000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64

Files In Submission

Name	View Source	Status
0000906709-21-000005-index-headers.html	Edgar Link	pending
0000906709-21-000005-index.html	Edgar Link	pending
0000906709-21-000005.txt	Edgar Link	pending
0000906709-21-000005-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20201231.htm	Edgar Link	pending
nktr-20201231.xsd	Edgar Link	pending
nktr-20201231xexx311.htm	Edgar Link	pending
nktr-20201231xexx312.htm	Edgar Link	pending
nktr-20201231xexx321.htm	Edgar Link	pending
nktr-20201231_cal.xml	Edgar Link	unprocessable
nktr-20201231_def.xml	Edgar Link	unprocessable
nktr-20201231_g1.jpg	Edgar Link	pending
nktr-20201231_htm.xml	Edgar Link	completed
nktr-20201231_lab.xml	Edgar Link	unprocessable
nktr-20201231_pre.xml	Edgar Link	unprocessable
nktr20201231-exx1035.htm	Edgar Link	pending
nktr20201231-exx1039.htm	Edgar Link	pending
nktr20201231-exx231.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2020 Q4 Form 10-K Financial Statement

#000090670921000005 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2020 Q4 Form 10-K Financial Statement

#000090670921000005 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr